Clinical trial
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma…
NCT00004017 · Peregrine Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00004017 |
|---|---|
| Title | Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma |
| Official title | Phase II Open-Label, Non-Randomized, Multicenter Study of Interstitial 131I-chTNT-1/B for the Treatment of Newly Diagnosed or Recurrent Malignant Glioma |
| Lead sponsor | Peregrine Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Procedure, Radiation |
| Interventions | conventional surgery, iodine I 131 monoclonal antibody TNT-1/B |
| Enrollment | 60 |
| Start date | Feb 1, 2000 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: